Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

284 ICODEXTRIN
Facial edema (5%)
Pruritus (>5%)
Rash (sic)
(2003): Frampton JE+, Drugs 63(19), 2079 (5%)
Vesiculobullous eruption (5%)
Pain (>5%)
Upper respiratory infection (15%)
IDARUBICIN
Synonyms: 4-demethoxydaunorubicin; 4-DMDR
Trade names: Idamycin (Pfizer); Zavedos
Indications: Acute myeloid leukemia
Category: Antibiotic, anthracycline
Half-life: 14–35 hours (oral)
Clinically important, potentially hazardous interactions
with: aldesleukin
Reactions
Skin
Acral erythema
(1993): Cohen PR, Cutis 51, 175
Bullous dermatitis (palms and soles)
Exanthems (10%)
(1998): Stuart NS+, Cancer Chemother Pharmacol 21, 351
(1997): Maloney DG+, J Clin Oncol 15, 3266
Urticaria (>10%)
(1997): Maloney DG+, J Clin Oncol 15, 3266
Mucosal
Mucositis (50%)
(2000): Creutzig U+, Klin Padiatr 212, 163
(1986): Dodion P+, Invest New Drugs 4, 31
Stomatitis (>10%)
Hair
Hair – alopecia (77%)
(2000): No author, Prescrire Int 9, 103
(1993): Ogawa M+, GanToKagukuRyoho(Japanese) 20, 897
(1993): Ogawa M+, GanToKagukuRyoho(Japanese) 20, 907
(1991): Hollingshead LM+, Drugs 42, 690
(1988): Gillies H+, Cancer Chemother Pharmacol 21, 261
(1986): Dodion P+, Invest New Drugs 4, 31
(1986): Lopez M+, Invest New Drugs 4, 39
Nails
Nails – pigmentation
(1997): Borecky Derrick J+, Cutis 59, 203
Other
Injection-site urticaria
IDEBENONE
Synonym: 6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4benzoquinone
Trade names: Avan; Mnesis
Indications: Alzheimer’s dementia, cardiovascular disease,
cerebrovascular disease, demyelination, depression, Friedreich’s
ataxia, improving memory, Leber’s hereditary optic neuropathy
Category: Coenzyme Q10 analog
Half-life: N/A
Clinically important, potentially hazardous interactions
with: None
None
IDURSULFASE
Reactions
Trade name: Elaprase (Shire)
Indications: Hunter syndrome, Mucopolysaccharidosis II
Category: Enzyme
Half-life: 46 minutes
Clinically important, potentially hazardous interactions
with: N/A
Reactions
Skin
Pruritus (28%)
Rash (sic) (13%)
Urticaria (16%)
Eyes
Visual disturbances (22%)
Other
Anaphylactoid reactions/Anaphylaxis
Application-site edema (13%)
Fever (63%)
Hypersensitivity
IFOSFAMIDE
Trade names: Holoxan; Ifex (Bristol-Myers Squibb); Ifoxan;
Mitoxana; Tronoxal
Indications: Cancers, sarcomas, leukemias, lymphomas
Category: Alkylating agent
Half-life: 4–15 hours
Clinically important, potentially hazardous interactions
with: aldesleukin, aprepitant
Reactions
Skin
Allergic reactions (sic) (1–10%)
Dermatitis (1–10%)
Pigmentation (1–10%)
(1994): Yule SM+, Cancer 73, 240
(1993): Teresi ME+, Cancer 71, 2873